MannKind (NASDAQ:MNKD) Price Target Raised to $12.00
MannKind (NASDAQ:MNKD – Free Report) had its price target lifted by Oppenheimer from $10.00 to $12.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on MNKD. Rodman & Renshaw initiated coverage […]
More Stories
The Goldman Sachs Group Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $180.00 to...
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research report sent...
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a research report issued to...
Alerus Financial (NASDAQ:ALRS) Upgraded at Raymond James
Raymond James upgraded shares of Alerus Financial (NASDAQ:ALRS – Free Report) from a market perform rating to an outperform rating...
Sanford C. Bernstein Cuts Airbnb (NASDAQ:ABNB) Price Target to $155.00
Airbnb (NASDAQ:ABNB – Free Report) had its price target trimmed by Sanford C. Bernstein from $174.00 to $155.00 in a...
Waystar Holding Corp. (NASDAQ:WAY) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Waystar Holding Corp. (NASDAQ:WAY – Get Free Report) have been given a consensus rating of “Buy” by the...